Universal Health Services 주식 (NYSE: UHS)

에 대한 최신 뉴스 Universal Health Services (NYSE:UHS) 주식

UNIVERSAL HEALTH SERVICES-B

Universal Health Servs

Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.

Universal Health Services

What Trump Said?

Government

News

Regulations

Health Care

Politics

Legal

Movers

General

NOVA

화요일 오후, 워싱턴 D.C.의 한 연방 판사가 도널드 트럼프 대통령이 모든 연방 보조금과 대출을 동결한 행정 명령을 일시적으로 차단했다. 이 명령은 3조 달러의 자금을 위험에 빠뜨리고 전체 산업을 불안하게 만들었다.

美 연방 판사가 트럼프의 연방 보조금 및 대출 동결 명령을 일시적으로 저지

Why It Matters

Equities

Large Cap

Sector ETFs

Econ #s

Markets

ETFs

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SEDG

백악관이 모든 연방 보조금과 대출에 대한 일시적인 동결을 명령하면서 3조 달러의 자금이 재검토를 받게 되었고, 이는 의회의 재정 권력에 대한 법적 및 정치적 충돌의 무대를 설정하여 광범위한 산업에 큰 영향을 미칠 수 있다. 이 지침은 월요일에 예산관리국(OMB)에 의해 발행되었고 여러 언론 매체에 의해 수신되었다. 모든 연방 기관은 프로그램이 도널드 트럼프 대통령의 정책 우선사항과 일치하는지 검토되는 동안 지급을 중단해야 한다.

트럼프의 연방 지출 중단으로 $3조가 위기에 봉착, 클린 에너지, 방산, 의료 등 산업이 위협

Deal Dispatch

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

새로이 등장한 블록 스타벅스(NASDAQ:SBUX)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 경제적 및 경쟁적 압박에 적응하기 위한 파트너십을 모색하고 있다.

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

Universal Health Services, Inc. Common Stock

Universal Health Services Inc

In the latest quarter, 5 analysts provided ratings for Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Universal Health Services and provided 12-month price targets. The average target is $221.4, accompanied by a high estimate of $249.00 and a low estimate of $200.00. Experiencing a 3.84% decline, the current average is now lower than the previous average price target of $230.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1742990554_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Universal Health Services. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$223.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$249.00</td>
<td>$271.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Universal Health Services. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Universal Health Services compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Universal Health Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Universal Health Services's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UHS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Universal Health Services analyst ratings.</a>
<h2>Unveiling the Story Behind Universal Health Services</h2>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Universal Health Services's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Universal Health Services displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 11.08%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Universal Health Services's net margin excels beyond industry benchmarks, reaching 8.08%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Universal Health Services's ROA excels beyond industry benchmarks, reaching 2.31%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.74, Universal Health Services adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Universal Health Services: 5 Analysts Share Their Views

Morgan Stanley analyst Craig Hettenbach initiates coverage on Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Equal-Weight rating and announces Price Target of $200.

Price Target

Initiation

Morgan Stanley Initiates Coverage On Universal Health Services with Equal-Weight Rating, Announces Price Target of $200

Wells Fargo analyst Stephen Baxter maintains Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and lowers the price target from $230 to $225.

Wells Fargo Maintains Overweight on Universal Health Services, Lowers Price Target to $225

4 analysts have shared their evaluations of Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $227.0, a high estimate of $249.00, and a low estimate of $210.00. This current average has decreased by 1.45% from the previous average price target of $230.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1740776419_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Universal Health Servs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$223.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$249.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$226.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Universal Health Servs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Universal Health Servs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Universal Health Servs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UHS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Universal Health Servs analyst ratings.</a>
<h2>Discovering Universal Health Servs: A Closer Look</h2>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Universal Health Servs: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Universal Health Servs showcased positive performance, achieving a revenue growth rate of 11.08% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Universal Health Servs's net margin is impressive, surpassing industry averages. With a net margin of 8.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.31%, the company showcases effective utilization of assets.
Debt Management: Universal Health Servs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.74.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Universal Health Servs Stands With Analysts

Stephens &amp; Co. analyst Scott Fidel maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Equal-Weight and raises the price target from $210 to $223.

Stephens & Co. Maintains Equal-Weight on Universal Health Servs, Raises Price Target to $223

Stephens &amp; Co. analyst Raj Kumar reiterates Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Equal-Weight and maintains $210 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Universal Health Servs, Maintains $210 Price Target

WIIM

Universal Health Services shares are trading higher after the company reported better-than-expected Q4 financial results.

Barclays analyst Andrew Mok maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and lowers the price target from $271 to $249.

Barclays Maintains Overweight on Universal Health Servs, Lowers Price Target to $249

Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) reported quarterly earnings of $4.92 per share which beat the analyst consensus estimate of $4.18 by 17.7 percent. This is a 57.19 percent increase over earnings of $3.13 per share from the same period last year. The company reported quarterly sales of $4.114 billion which beat the analyst consensus estimate of $4.010 billion by 2.59 percent. This is a 11.07 percent increase over sales of $3.704 billion the same period last year.

Earnings

Earnings Beats

Universal Health Servs Q4 2024 Adj. EPS $4.92 Beats $4.18 Estimate, Sales $4.114B Beat $4.010B Estimate

Shares of healthcare stocks are trading lower after President Trump signed an executive order on healthcare price transparency.

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

A nationwide lockout of federal health payment systems, reportedly due to an &#8220;outage&#8221;, has led to widespread criticism of the White House. The lockout affected several organizations and agencies, including state Medicaid programs, federally funded Head Start early education programs, and community health centers.
What Happened: The White House attributed the lockout to an &#8220;outage.&#8221; White House Press Secretary Karoline Leavitt said on X that the administration is &#8220;aware&#8221; of the Medicaid website not functioning.
&#8220;We have confirmed no payments have been affected — they are still being processed and sent,&#8221; said Leavitt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The White House is aware of the Medicaid website portal outage. We have confirmed no payments have been affected — they are still being processed and sent. We expect the portal will be back online shortly.
&mdash; Karoline Leavitt (@PressSec) <a href="https://twitter.com/PressSec/status/1884329868030271759?ref_src=twsrc%5Etfw">January 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The lockout prevented multiple state Medicaid programs from accessing their payment systems. However, operations resumed later the same day, according to a CBS News <a href="https://www.cbsnews.com/news/medicaid-head-start-health-centers-trump-funding-freeze/">report</a>. The incident coincided with President Donald Trump&#8217;s controversial decision to freeze spending across the federal government, leading to heightened criticism from state governments, nonprofits, and lawmakers.
The entities affected were unable to access the Payment Management Services web portal, run by the Department of Health and Human Services (HHS), which processes billions of dollars in payments annually. 
The lockout and the ongoing communication &#8220;pause&#8221; imposed by the Trump administration at HHS led to a flurry of requests for comment from various stakeholders, including the National Association of Medicaid Directors and several lawmakers.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43293219/teslas-30k-ev-risks-being-a-nothing-burger-says-gary-black-warns-of-cannibalization-without-a-new-compact-design">Tesla&#8217;s $30K EV Risks Being A &#8216;Nothing Burger,&#8217; Says Gary Black—Warns Of Cannibalization Without A New Compact Design</a>
Why It Matters: The lockout occurred amidst the administration&#8217;s decision to freeze spending across the federal government, a move that has been challenged legally. A federal judge issued a <a href="https://www.benzinga.com/government/regulations/25/01/43292056/judge-blocks-trumps-order-to-freeze-federal-grant-money">temporary stay on the funding freeze</a>, halting the move until further arguments can be heard.
The freeze put<a href="https://www.benzinga.com/25/01/43290381/trumps-federal-spending-freeze-puts-3-trillion-in-limbo-threatens-industries-like-clean-energy-defense-healthcare"> $3 trillion in funding under scrutiny</a>. This directive required all federal agencies to halt disbursements while programs were reviewed for alignment with Trump&#8217;s policy priorities.
The move is expected to hit sectors such as healthcare, education, clean energy and others. Stocks of clean energy companies like Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>). and Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) suffered a downturn. Shares of healthcare-sector firms like Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) and Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) also were in the red on Tuesday.
Photo Courtesy: Shutterstock.com
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43293715/cathie-wood-dumps-tesla-stock-ahead-of-q4-earnings-ark-invest-loads-up-on-amazon">Cathie Wood Dumps Tesla Stock Ahead Of Q4 Earnings, Ark Invest Loads Up On Amazon</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Trump White House Blames 'Outage' For Medicaid Website Lockout: 'We Have Confirmed No Payments Have Been Affected'

A federal judge in the District of Columbia on Tuesday afternoon temporarily blocked an executive order given by President Donald Trump that imposed a freeze of all federal grants and loans, putting $3 trillion in funding in jeopardy and <a href="https://www.benzinga.com/25/01/43290381/trumps-federal-spending-freeze-puts-3-trillion-in-limbo-threatens-industries-like-clean-energy-defense-healthcare">entire industries on edge.&nbsp;</a>
The Details: According to a New York Times <a href="https://www.nytimes.com/2025/01/28/us/politics/trump-funding-freeze-blocked.html">report</a>, Judge Loren AliKhan blocked the order late Tuesday afternoon in response to a lawsuit filed by Democracy Forward. The lawsuit argued the directive violated the First Amendment and the Administrative Procedures Act governing the issuance of executive orders. 
Judge AliKhan said she will issue a more permanent decision on Feb. 3 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
Skye Perryman, Democracy Forward's president and chief executive, commented on the judge's decision in a statement.&nbsp;
"We are grateful for this administrative stay to allow our clients time to sort through the chaos created by the Trump administration's hasty and ill-advised actions," Perryman said, per the New York Times. 
Trump's directive, issued Monday by the Office of Management and Budget, required federal agencies to halt disbursements while programs were reviewed for alignment with Trump administration policies and was slated to go into effect on Tuesday at 5 p.m. ET.&nbsp;
But, early Tuesday, state Medicaid programs reported the federal reimbursement portals had been locked. State officials said funding for community health centers, food for families, housing assistance, preschools and disaster relief was in limbo.
According to the New York Times, the White House and OMB said on Tuesday afternoon the funding freeze did "not apply across-the-board" and affected programs on D.E.I. efforts and funding for organizations "that undermine the national interest."
Stocks To Watch: It remains unclear exactly which industries could be affected by Trump's order or if the judge will elect to block it permanently on Feb 3.&nbsp;
However, Medicaid funding had reportedly been stopped at least temporarily. HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stocks fell on Tuesday. 
Large defense contractors like RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) also face a growing degree of uncertainty regarding government funding and contracts.
Green industries including solar energy could also be on the chopping block for federal funding due to Trump administration policies. Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12% Tuesday and Sunrun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% amid the uncertainty on future policy changes. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Judge Blocks Trump's Order To Freeze Federal Grant Money

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and setting the stage for a legal and political showdown over the congressional power of the purse that could heavily impact a <a href="https://www.benzinga.com/markets">wide range of industries.</a>
The directive, issued Monday by the Office of Management and Budget and received by several media outlets, requires all federal agencies to halt disbursements while programs are reviewed for alignment with President Donald Trump's policy priorities.
This includes halting new awards, existing payment and funding for projects until reviewed.
The exact financial impact of the order remains uncertain. Budget experts cited <a href="https://www.washingtonpost.com/business/2025/01/28/trump-spending-freeze-upends-washington-triggering-legal-threats-delays/">by the Washington Post </a>estimate at least tens of billions of dollars are at stake, though the White House directive suggests the total could be significantly higher.
Of the almost $10 trillion spent by the federal government in fiscal 2024, more than $3 trillion was federal financial assistance, Matthew Vaeth, acting director at the OMB, said in the memorandum.
&#8220;Financial assistance should be dedicated to advancing Administration priorities,&#8221; Vaeth said, adding that &#8220;the use of Federal resources to advance Marxist equity, transgenderism, and green new deal social engineering policies is a waste of taxpayer dollars that does not improve the day-to-day lives of those we serve.&#8221;
The White House said that Social Security and Medicare remain untouched. The sweeping pause threatens funding for universities, nonprofits, contractors and private companies that depend on federal assistance.
&#8220;Nothing in this memo should be construed to impact Medicare or Social Security benefits,&#8221; the memo said. 
The immediate focus will be on how agencies handle exemptions. The OMB memo allows federal departments to request case-by-case approvals, which means some funding may still flow, but the process is likely to be slow and politically charged.
Federal agencies have until Feb. 10, 2025, to provide OMB with detailed reports outlining which programs, projects, and activities are affected by the funding pause.
<h3 class="wp-block-heading">Legal, Political Showdown Over Federal Funds </h3>
The move is triggering legal challenges from nonprofits and Democratic-led states.
Within hours of the announcement, lawsuits were filed in federal courts in New York, Illinois and Oregon, arguing that Trump does not have the authority to withhold congressionally approved spending.
Senate Minority Leader Chuck Schumer was among the first to push back, saying Congress-approved investments are legally mandated and asserting the president lacks the authority to override the Impoundment Control Act of 1974, which restricts unilateral executive control over federal funds.
Trump has long argued that the 1974 law is unconstitutional, stating that past presidents had far more discretion over spending before its passage.
<h3 class="wp-block-heading">Which Industries Could Face Trouble?</h3>
Some of the hardest-hit sectors could include clean energy, defense, health care and education, where federal dollars have played a crucial role in driving investment and growth in recent years.
Trump's OMB memo explicitly targeted climate initiatives and green energy programs. Shares of solar and renewable energy companies were among the hardest hit following the federal funding freeze.
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and the Invesco Wilderhill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) fell by 2% and 1.3%, respectively, on Tuesday. 
Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12%, Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% and SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 5%. 
Defense contractors such as Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) may also see rising uncertainty. While military spending is unlikely to be cut outright, several defense contractors rely on federal grants for research and development. 
The impact on health care remains unclear. While Medicare is shielded, Medicaid funding — which supports hospitals, managed care providers and pharmaceutical companies — could be at risk.
HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) fell by 1% and 1.4%, respectively, while Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) showed resilience Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43281252/fed-set-to-signal-no-rush-to-cut-rates-as-wall-street-awaits-policy-clarity">Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity</a></li>
</ul>
Photo via Shutterstock.

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care

JP Morgan analyst Benjamin Rossi assumes Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Neutral rating and announces Price Target of $226.

JP Morgan Assumes Universal Health Servs at Neutral, Announces Price Target of $226

Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) has outperformed the market over the past 20 years by 2.63% on an annualized basis producing an average annual return of 11.02%. Currently, Universal Health Servs has a market capitalization of $12.30 billion. 
Buying $1000 In UHS: If an investor had bought $1000 of UHS stock 20 years ago, it would be worth $8,258.43 today based on a price of $186.44 for UHS at the time of writing.
<h3>Universal Health Servs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734107408_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Universal Health Servs 20 Years Ago Would Be Worth This Much Today

TD Cowen analyst Ryan Langston maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Buy and lowers the price target from $275 to $251.

TD Cowen Maintains Buy on Universal Health Servs, Lowers Price Target to $251

Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) has outperformed the market over the past 20 years by 3.09% on an annualized basis producing an average annual return of 11.47%. Currently, Universal Health Servs has a market capitalization of $13.12 billion. 
Buying $1000 In UHS: If an investor had bought $1000 of UHS stock 20 years ago, it would be worth $8,729.59 today based on a price of $198.86 for UHS at the time of writing.
<h3>Universal Health Servs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732566672_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,700 Today

12 analysts have expressed a variety of opinions on Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $248.58, a high estimate of $285.00, and a low estimate of $211.00. This upward trend is evident, with the current average reflecting a 3.65% increase from the previous average price target of $239.83.
<img src="https://www.benzinga.com/files/images/story/2024/1732554065_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Universal Health Servs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Frank Morgan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$211.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$271.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$283.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$222.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$274.00</td>
<td>$236.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Universal Health Servs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Universal Health Servs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Universal Health Servs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Universal Health Servs analyst ratings.</a>
<h2>All You Need to Know About Universal Health Servs</h2>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Universal Health Servs's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Universal Health Servs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.23%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Universal Health Servs's net margin is impressive, surpassing industry averages. With a net margin of 6.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Universal Health Servs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.95% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Universal Health Servs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.82% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Universal Health Servs's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 12 Analyst Evaluations For Universal Health Servs

Press Releases

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DATE FOR THIRD QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL

United Health Services (UHS) Now Offering Incisionless Focused Ultrasound Treatment for Patients with Essential Tremor

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 THIRD QUARTER FINANCIAL RESULTS

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT THE 2024 WOLFE RESEARCH HEALTHCARE CONFERENCE

Dividends

UNIVERSAL HEALTH SERVICES, INC.ANNOUNCES DIVIDEND

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR EARNINGS RELEASE AND CONFERENCE CALL

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DIVIDEND

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT MARCH HEALTHCARE CONFERENCES

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND 2025 OPERATING RESULTS FORECAST

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT KEYBANC CAPITAL MARKETS VIRTUAL HEALTHCARE FORUM

Comments

Universal Health Services

뉴스

에 대한 최신 뉴스 Universal Health Services (NYSE:UHS) 주식

수요일, 1월 29, 2025

화요일, 1월 28, 2025

토요일, 11월 23, 2024

일요일, 11월 17, 2024

토요일, 10월 26, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌